Bio Medica LaboratoriesNSE:BMLL +0.49%14 ROE % is 99.59% as of Mar. 2025, which is 47% above its 10-year median of 67.74. GuruFocus rates NSE:BMLL with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 98.37% on this metric.
The historical rank and industry rank for Bio Medica Laboratories's ROE % or its related term are showing as below:
NSE:BMLL'
s ROE % Range Over the Past 10 Years
Min: 13.67 Med: 67.74 Max: 99.59
Current: 99.59
During the past 3 years, Bio Medica Laboratories's highest ROE % was 99.59%. The lowest was 13.67%. And the median was 67.74%.
NSE:BMLL's ROE % is ranked better than 98.37% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs NSE:BMLL: 99.59
Bio Medica Laboratories (NSE:BMLL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Mar. 2025) net income data. The Revenue data used here is one times the annual (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories ROE % Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
ROE %
13.67
67.74
99.59
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
ROE %
13.67
67.74
99.59
NSE:BMLL vs ISRG, BDX, MDLN: ROE % Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's ROE % distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Bio Medica Laboratories (NSE:BMLL) has a ROE % of 99.59% as of Mar. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bio Medica Laboratories and its competitors. This is 47% above median its historical median of 67.74. Over the past decade, Bio Medica Laboratories' ROE % has ranged from 13.67 to 99.59. According to the industry distribution chart, Bio Medica Laboratories ranks #13 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 1.6%.
Is Bio Medica Laboratories' ROE % too high?
Bio Medica Laboratories' current ROE % of 99.59% is 47% above median its 10-year median of 67.74. Over the past 10 years, this metric has ranged from a low of 13.67 to a high of 99.59. The Medical Devices & Instruments industry median ROE % is 2.40. Bio Medica Laboratories' value of 99.59% is 4049.6% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #13 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #13 out of 797 companies for ROE %. This places Bio Medica Laboratories in the top 2% of its industry — outperforming the majority of peers. The industry median ROE % is 2.40. Bio Medica Laboratories' value of 99.59% is 4049.6% above this benchmark. Historically, Bio Medica Laboratories' own ROE % has ranged from 13.67 to 99.59 over the past decade. While the company's 10-year median is 67.74 vs. the industry median of 2.40, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.40, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current ROE % of 99.59% is 4049.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current ROE % is 99.59%, which is 47% above median its own 10-year median of 67.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current ROE % of 99.59%. The current ROE % is 99.59%, which is 47% above median its 10-year median of 67.74 and 4049.6% above the Medical Devices & Instruments industry median of 2.40. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current ROE % is 99.59% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score
Get the complete analysis for NSE:BMLL
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 